REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. In addition, it also develops RGX-121 for the treatment of mucopolysaccharidosis type II and is in Phase III clinical trial; RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. Further, the company also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Details
Account Type
CFD Trading: MetaTrader 5
CFD Trading: MetaTrader 5
Investing: Web
Commission
0.1%
Trading schedule (UTC)
Open NowClosed NowCloses onOpening on
at
-
This shows the opening hours in your local time zone
(UTC)
Open an account and start investing with Metadoro now. Invite friends and get rewarded for their active trading. You can learn more about the affiliate program in your personal account.
Thank you for visiting metadoro.com. This website is managed by RHC Investments, which is authorised and regulated as an Investment Dealer by the Financial Services Commission of Mauritius with License number C115015381. Mauritius is not part of the European regulatory framework and is not in scope of (among others) the Markets in Financial Instruments Directive (MiFID) II.
By continuing you confirm that the decision is made independently and at your own exclusive initiative and that no solicitation or recommendation has been made by RHC Investments.
Create a NewsletterCreate a Newsletter
Customize your subscriptions the way you want!
Analytics
Get notified upon new posts
Select category
Price alerts
Discover timely market up-and-downs, pumps, etc.
Select category
Alert method
All categoriescategoriesAll instrumentsinstrumentssearchNothing found